Cargando…

Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

BACKGROUND: This study compared the long-term efficacy of different durations of adjuvant chemotherapy for patients with gastric cancer after radical gastrectomy with D2 lymphadenectomy. METHODS: We retrospectively identified 428 patients with stage II–III gastric cancer who underwent D2 gastrectomy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lei, Zhang, Chenghai, Yao, Zhendan, Cui, Ming, Xing, Jiadi, Yang, Hong, Zhang, Nan, Liu, Maoxing, Xu, Kai, Tan, Fei, Li, Yuzhe, Jiang, Beihai, Su, Xiangqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406722/
https://www.ncbi.nlm.nih.gov/pubmed/34461860
http://dx.doi.org/10.1186/s12885-021-08717-4
_version_ 1783746545599905792
author Chen, Lei
Zhang, Chenghai
Yao, Zhendan
Cui, Ming
Xing, Jiadi
Yang, Hong
Zhang, Nan
Liu, Maoxing
Xu, Kai
Tan, Fei
Li, Yuzhe
Jiang, Beihai
Su, Xiangqian
author_facet Chen, Lei
Zhang, Chenghai
Yao, Zhendan
Cui, Ming
Xing, Jiadi
Yang, Hong
Zhang, Nan
Liu, Maoxing
Xu, Kai
Tan, Fei
Li, Yuzhe
Jiang, Beihai
Su, Xiangqian
author_sort Chen, Lei
collection PubMed
description BACKGROUND: This study compared the long-term efficacy of different durations of adjuvant chemotherapy for patients with gastric cancer after radical gastrectomy with D2 lymphadenectomy. METHODS: We retrospectively identified 428 patients with stage II–III gastric cancer who underwent D2 gastrectomy between 2009 and 2016. Patients were divided into four groups according to the duration of adjuvant chemotherapy, including 0 week (no adjuvant, group A), 20 to 24 weeks (completed 7–8 cycles every 3 weeks or 10–12 cycles every 2 weeks, group B), and 12 to18 weeks (completed 4–6 cycles every 3 weeks or 6–9 cycles every 2 weeks, group C), and less than 12 weeks (received up to 3 cycles every 3 weeks or 5 cycles every 2 weeks, group D). The chemotherapy regimens included XELOX, SOX, and FOLFOX. 5-year overall survival (OS) and disease-free survival (DFS) were analyzed. RESULTS: The 5-year OS rates for groups A, B, C, and D were 52.3, 73.7, 72.0, and 53.3%, respectively, and the 5-year DFS rates were 50.0, 68.0, 65.4, and 50.0%, respectively. OS and DFS were higher in group B than in groups A and D. Similarly, patients in group C were more likely to have higher OS and DFS than those in groups A and D. Meanwhile, there were no significant differences in OS and DFS between groups B and C. The multivariate analysis confirmed with high statistical significance the efficacy of complete courses of adjuvant chemotherapy, and, among them, the similar impact of 4–6/6–9 and 7–8/10–12 cycles, resulting in similar HRs vs Group A (0.52 and 0.42, respectively). CONCLUSIONS: To reduce toxicity and maintain efficacy, XELOX or SOX chemotherapy regimens administered for 4–6 cycles every 3 weeks or FOLFOX regimen for 6–9 cycles every 2 weeks might be a favorable option for patients with stage II–III gastric cancer after D2 gastrectomy. Prospective multicenter clinical trials with adequate sample sizes are necessary to verify these findings.
format Online
Article
Text
id pubmed-8406722
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84067222021-08-31 Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study Chen, Lei Zhang, Chenghai Yao, Zhendan Cui, Ming Xing, Jiadi Yang, Hong Zhang, Nan Liu, Maoxing Xu, Kai Tan, Fei Li, Yuzhe Jiang, Beihai Su, Xiangqian BMC Cancer Research Article BACKGROUND: This study compared the long-term efficacy of different durations of adjuvant chemotherapy for patients with gastric cancer after radical gastrectomy with D2 lymphadenectomy. METHODS: We retrospectively identified 428 patients with stage II–III gastric cancer who underwent D2 gastrectomy between 2009 and 2016. Patients were divided into four groups according to the duration of adjuvant chemotherapy, including 0 week (no adjuvant, group A), 20 to 24 weeks (completed 7–8 cycles every 3 weeks or 10–12 cycles every 2 weeks, group B), and 12 to18 weeks (completed 4–6 cycles every 3 weeks or 6–9 cycles every 2 weeks, group C), and less than 12 weeks (received up to 3 cycles every 3 weeks or 5 cycles every 2 weeks, group D). The chemotherapy regimens included XELOX, SOX, and FOLFOX. 5-year overall survival (OS) and disease-free survival (DFS) were analyzed. RESULTS: The 5-year OS rates for groups A, B, C, and D were 52.3, 73.7, 72.0, and 53.3%, respectively, and the 5-year DFS rates were 50.0, 68.0, 65.4, and 50.0%, respectively. OS and DFS were higher in group B than in groups A and D. Similarly, patients in group C were more likely to have higher OS and DFS than those in groups A and D. Meanwhile, there were no significant differences in OS and DFS between groups B and C. The multivariate analysis confirmed with high statistical significance the efficacy of complete courses of adjuvant chemotherapy, and, among them, the similar impact of 4–6/6–9 and 7–8/10–12 cycles, resulting in similar HRs vs Group A (0.52 and 0.42, respectively). CONCLUSIONS: To reduce toxicity and maintain efficacy, XELOX or SOX chemotherapy regimens administered for 4–6 cycles every 3 weeks or FOLFOX regimen for 6–9 cycles every 2 weeks might be a favorable option for patients with stage II–III gastric cancer after D2 gastrectomy. Prospective multicenter clinical trials with adequate sample sizes are necessary to verify these findings. BioMed Central 2021-08-30 /pmc/articles/PMC8406722/ /pubmed/34461860 http://dx.doi.org/10.1186/s12885-021-08717-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Chen, Lei
Zhang, Chenghai
Yao, Zhendan
Cui, Ming
Xing, Jiadi
Yang, Hong
Zhang, Nan
Liu, Maoxing
Xu, Kai
Tan, Fei
Li, Yuzhe
Jiang, Beihai
Su, Xiangqian
Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
title Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
title_full Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
title_fullStr Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
title_full_unstemmed Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
title_short Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study
title_sort adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with d2 lymphadenectomy: a retrospective control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406722/
https://www.ncbi.nlm.nih.gov/pubmed/34461860
http://dx.doi.org/10.1186/s12885-021-08717-4
work_keys_str_mv AT chenlei adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT zhangchenghai adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT yaozhendan adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT cuiming adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT xingjiadi adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT yanghong adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT zhangnan adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT liumaoxing adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT xukai adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT tanfei adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT liyuzhe adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT jiangbeihai adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy
AT suxiangqian adjuvantchemotherapyisanadditionaloptionforlocallyadvancedgastriccancerafterradicalgastrectomywithd2lymphadenectomyaretrospectivecontrolstudy